Investigational drug · Phase 2
NLM-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Untreated, Advanced Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "NLM-001"
First trial start
2021
Sep 1, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NLM-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Untreated
- Advanced Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NLM-001" as an intervention, largest first.
- A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.Not yet recruiting
Nelum CorpIndustry
NCT07578337 · 40 participants (planned) · Start Jul 15, 2026 · Primary completion Feb 28, 2029
Drug: Gemcitabine (1000 mg/m2); Nab-paclitaxel (Abraxane) and 3 more · For: Untreated; Advanced Pancreatic Cancer
Sites: Zaragoza, Spain; Barcelona, Spain; Santander, Spain · 6 sites in all
- Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerActive, not recruiting
Nelum CorpIndustry
NCT04827953 · 28 participants · Start Sep 1, 2021 · Primary completion Apr 2025
Drug: Gemcitabine; Nab paclitaxel and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Santiago de Compostela, Spain; Málaga, Spain; Zaragoza, Spain · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Untreated
- BotensilimabAGEN1181, 8541APhase 24 trials
Agenus Inc. · Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated
- BalstililmabPhase 21 trial
Nelum Corp · Untreated, Advanced Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.